(Q37668684)

21 August 2017

1 reference

title

Neurotransmission in Parkinson's disease: beyond dopamine (English)

1 reference

21 August 2017

0 references

1 reference

P Barone

1

1 reference

21 August 2017

publication date

30 December 2009

1 reference

European Journal of Neurology

21 August 2017

published in

1 reference

21 August 2017

volume

17

1 reference

21 August 2017

issue

3

1 reference

21 August 2017

page(s)

364-376

1 reference

How common are the "common" neurologic disorders?

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Parkinson's disease: clinical features and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Non-motor symptoms of Parkinson's disease: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Diagnostic staging of Parkinson's disease: conceptual aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Anatomy, physiology, and pharmacology of the basal ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Pathophysiology of parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Parallel and interactive learning processes within the basal ganglia: relevance for the understanding of addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Cognitive- and movement-related potentials recorded in the human basal ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Learning and memory functions of the Basal Ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Complementary roles of basal ganglia and cerebellum in learning and motor control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Reward-guided learning beyond dopamine in the nucleus accumbens: the integrative functions of cortico-basal ganglia networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Temporal dynamics of basal ganglia response and connectivity during verbal working memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

The cognitive functions of the caudate nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Basal ganglia lesions and the theory of fronto-subcortical loops: neuropsychological findings in two patients with left caudate lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Behavioural disorders induced by external globus pallidus dysfunction in primates: I. Behavioural study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Bladder and bowel dysfunction in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Serotonin-dopamine interactions in the control of conditioned reinforcement and motor behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Psychiatric comorbidity in a population of Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Current approaches to management of depression in Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Motor changes during sertraline treatment in depressed patients with Parkinson's disease*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Norepinephrine and dopamine as learning signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

REM sleep behaviour disorder in Parkinson's disease is associated with specific motor features

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

REM behavior disorder, hallucinations and cognitive impairment in Parkinson's disease: a two-year follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Approaching disturbed sleep in late Parkinson's Disease: first step toward a proposal for a revised UPDRS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Paradoxical (REM) sleep genesis: the switch from an aminergic-cholinergic to a GABAergic-glutamatergic hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Beating a dead horse: dopamine and Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Stages in the development of Parkinson's disease-related pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Cognitive profile of patients with newly diagnosed Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Basal forebrain neurons in the dementia of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Cholinergic-dependent cognitive deficits in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Rivastigmine for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Nicotinic receptors as CNS targets for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Autonomic Nervous System Dysfunction in Parkinson's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Invited Article: Autonomic ganglia: target and novel therapeutic tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Pre- and postsynaptic serotoninergic excitation of globus pallidus neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Assessment of depression in three medically ill, elderly populations: Alzheimer's disease, Parkinson's disease, and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

A controlled trial of antidepressants in patients with Parkinson disease and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

The neuropathological basis for depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Pain in Parkinson's disease: Prevalence and characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

5-HT1A receptor, an old target for new therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Noradrenaline in Parkinson's disease: from disease progression to current therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Noradrenergic drugs for levodopa-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Non-dopaminergic treatments in development for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Drug Insight: new drugs in development for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Prevalence of orthostatic hypotension in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Noradrenergic pain modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Intrinsic membrane properties and synaptic inputs regulating the firing activity of the dopamine neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Metabotropic glutamate receptors in the basal ganglia motor circuit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Metabotropic glutamate receptors: beyond the regulation of synaptic transmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Distinct roles of group I mGlu receptors in striatal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Dopamine/glutamate interactions in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

AMPA receptor potentiators: application for depression and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Glutamate and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Adenosine A2A receptors and basal ganglia physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Novel pharmacological strategies for motor complications in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Somnolence and other sleep disorders in Parkinson's disease: the challenge for the practicing neurologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Adenosine inhibits activity of hypocretin/orexin neurons by the A1 receptor in the lateral hypothalamus: a possible sleep-promoting effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Hypocretin (orexin) cell loss in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Therapeutic potential of group III metabotropic glutamate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Role of GABA in anxiety and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Dopamine and the regulation of cognition and attention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Cholinergic mediation of attention: contributions of phasic and tonic increases in prefrontal cholinergic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Treatment of early Parkinson's disease. Part 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Are dopaminergic pathways involved in theory of mind? A study in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Serotonin/dopamine interaction in memory formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

A dopaminergic basis for working memory, learning and attentional shifting in Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Fatigue in levodopa-naive subjects with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Octopamine-mediated neuronal plasticity in honeybees: implications for olfactory dysfunction in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

The role of the basal ganglia in nociception and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

Early abnormalities of vascular and cardiac autonomic control in Parkinson's disease without orthostatic hypotension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02900.X

10.1111/J.1468-1331.2009.02900.X

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference